Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
They are used primarily in the treatment of type 2 diabetes and obesity
Use of medications intended to promote weight loss, within 6 months prior to screening, including, but not limited to, the following: Saxenda (liraglutide 3.0 mg) or other GLP-1RA Wegovy or Ozempic (semaglutide) Xenical or Alli (orlistat) Meridia (sibutramine) Acutrim (phenylpropanolamine) Sanorex (mazindol) Adipex or Lomaira (phentermine) Belviq (lorcaserin) Qsymia (phenterminetopiramate combination) Contrave (naltrexone when combined with bupropion) Zepbound or Mounjaro (tirzepatide) Other similar body-weight-loss medication, including over-the-counter medications (for example, Alli) 35
Sometimes, small clinical adjustments lead to noticeable progress quickly
No regulatory agency anywhere in the world has approved BPC-157 for any indication
